Bristol Myers Squibb Secures Dual Regulatory Wins for Opdivo® in Classical Hodgkin Lymphoma
Bristol Myers Squibb (NYSE: BMY) announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and...
FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo announced that the US Food and Drug Administration (FDA) has approved Datroway(datopotamab deruxtecan) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC)...
Cipla Revolutionizes Respiratory Care with Launch of Ciposcillo®️, India’s First Next-Gen Tidal-Breathing Diagnostic Device
Cipla Limited (announced the launch of Ciposcillo®, a next-generation oscillometer designed for the precise assessment of respiratory mechanics. This advanced device is engineered to provide early...
Zydus Fast-Tracks Malaria Fight: DCGI Greenlights Phase III Trials for Breakthrough Drug Zintrodiazine
Zydus Lifesciences Limited (“Zydus”), a leading innovation-driven global lifesciences company, has received regulatory approval from the Drugs Controller General of India (DCGI) to commence two Phase...
Lupin Limited Secures U.S. FDA Nod for Glycerol Phenylbutyrate Oral Liquid in Urea Cycle Disorders
Lupin has announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application...
New Meta-Analysis Ranks CAPLYTA®️ Lumateperone First in Efficacy and Metabolic Safety for Adjunctive MDD Treatment
Intra-Cellular Therapies, Inc. announced the presentation of a new network meta-analysis (NMA) demonstrating that CAPLYTA® (lumateperone) showed the greatest improvement across four key efficacy outcomes among...